AllSci News
Frontier Biotech and GSK sign USD 1b. exclusive licensing deal for siRNA kidney disease therapies
Frontier Biotechnologies Inc., a Nanjing, China-headquartered biopharma company, announced an exclusive licensing agreement with GSK, the London-based...
PBS293-MMAE preclinical data from Promatix Biosciences show promise in colorectal cancer models
UK-based Promatix Biosciences announced preclinical data for PBS293-MMAE, a first-in-class cis-bispecific antibody-drug conjugate targeting both EGFR and...
Boehringer Ingelheim licenses preclinical immunometabolic program from Sitryx Therapeutics for over USD 500m
Boehringer Ingelheim (Ingelheim am Rhein, Germany) and Sitryx Therapeutics (Oxford, UK) announced on 26 February 2026 that Boehringer has acquired an...
Shionogi Acquires Apnimed's SASS Joint Venture Stake for USD 150m to Consolidate Sleep Medicine Portfolio
Shionogi & Co., Ltd. has entered a definitive agreement to acquire Apnimed, Inc.'s 50% ownership of the Shionogi-Apnimed Sleep Science, LLC (SASS) joint...
Aprea Therapeutics secures Australian and Japanese patents for WEE1 and ATR inhibitor cancer programs
Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company headquartered in the US, announced the expansion of its global...
FDA Grants Sanofi's Venglustat Breakthrough Therapy Designation for Type 3 Gaucher Disease Treatment
Sanofi (EURONEXT: SAN; NASDAQ: SNY), a Paris-headquartered biopharma company, announced that the US FDA has granted Breakthrough Therapy designation to...
Collegium acquires ADHD drug AZSTARYS from Corium Therapeutics for USD 650m plus milestones
Collegium Pharmaceutical, based in Stoughton, Massachusetts, announced a definitive agreement to acquire AZSTARYS from Corium Therapeutics Holdings for USD...
Eli Lilly's lebrikizumab delivers positive Phase 3 results in pediatric atopic dermatitis trial
Eli Lilly announced positive Phase 3 results for EBGLYSS (lebrikizumab-lbkz) in pediatric patients aged six months to 18 years with moderate-to-severe...
Compass Therapeutics Launches Phase 1 Trial of CTX-10726 PD-1×VEGF-A Bispecific in Advanced Cancers
Compass Therapeutics (NASDAQ: CMPX) has registered a Phase 1 CTX-10726 clinical trial (NCT07419841) that will mark the first time the tetravalent PD-1 ×...
ARTHEx Biotech Secures FDA Fast Track Designation for ATX-01 in Myotonic Dystrophy Type 1
ARTHEx Biotech, a clinical-stage biotechnology company headquartered in Valencia, Spain, announced that the U.S. Food and Drug Administration (FDA) has...
R1 Therapeutics Launches With Oversubscribed $77.5 Million Series A for Kidney Disease Therapies
R1 Therapeutics, a clinical-stage biopharmaceutical company headquartered in Redwood City, California, has launched with an oversubscribed Series A...
Altesa BioSciences Closes USD 75 Million Series B to Advance Rhinovirus Antiviral Therapy
Altesa BioSciences, a clinical-stage company headquartered in Atlanta focused on developing antiviral therapies for chronic lung disease, has closed an...
Artelo Biosciences raises USD 11m in private placement
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company based in Solana Beach, California, announced an Artelo $11 million private...
Acurx Pharmaceuticals Secures US Patent for Innovative DNA Polymerase IIIC Inhibitor Technology
USPTO Grants Acurx Pharmaceuticals Patent for Innovative DNA Polymerase IIIC Inhibitor Technology
Cancer Grand Challenges Awards USD 125M in Series Grants to Five Global Research Teams
Cancer Grand Challenges Awards USD 125m to Five Global Research Teams
The AllSci Brief
Free, systematic R&D and deal news. Daily.